The final overall-survival analysis of the FLAURA trial established osimertinib as a major first-line option for patients with advanced non-small-cell lung cancer harboring sensitizing EGFR mutations. In previously untreated patients, osimertinib produced a longer median overall survival than standard first-generation EGFR tyrosine kinase inhibitors. The survival benefit was achieved while maintaining a broadly comparable overall safety profile, despite longer treatment exposure. For HCPs, the study demonstrates the clinical importance of obtaining molecular results before selecting systemic therapy in appropriate advanced NSCLC. It also shows how treatment sequencing has evolved: targeted therapy can be selected up front when a relevant driver alteration is identified, rather than relying solely on histology and clinical stage. This fits the NAPCON lung-cancer sessions on biomarker testing and access to modern staging and treatment pathways. The paper should not be generalized to EGFR-negative disease, but it provides a clear example of how biomarker-driven treatment can change outcomes in a defined molecular subgroup. In multidisciplinary practice, the result reinforces the value of coordinated pathology, molecular testing, imaging and oncology decision-making.